Case series:autologous anti-CD19 chimeric antigen receptor T cells treatment

2 trials

Sponsors

Dongguan Taixin Hospital

Conditions

Relapsed or refractory B acute lymphoblastic leukemia

Unknown Phase

Phase I study of autologous anti-CD19 chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia

RecruitingChiCTR1900020639

Dongguan Taixin HospitalRelapsed or refractory B acute lymphoblastic leukemia

Start: 2019-01-02Updated: 2019-01-14

Phase I study of autologous anti-CD22 chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia

RecruitingChiCTR1900020666

Dongguan Taixin HospitalRelapsed or refractory B acute lymphoblastic leukemia

Start: 2019-01-02Updated: 2019-01-14